Ignite Connect 2026 | Jonathan Villena-Vargas - LNT Bio: A New Approach to Solid Tumor Immunotherapy скачать в хорошем качестве

Ignite Connect 2026 | Jonathan Villena-Vargas - LNT Bio: A New Approach to Solid Tumor Immunotherapy

LymphNodeTx is developing a new approach to solid tumor immunotherapy by sourcing tumor-recognizing T cells from benign draining lymph nodes. In this Ignite Connect pitch, thoracic surgeon and co-founder Dr. Jonathan Villena shares how this novel strategy enables scalable, closed-system cell manufacturing without the toxicity and delays associated with TIL therapy. By bypassing exhausted tumor-infiltrating lymphocytes and instead using healthy, stem-like T cells from mapped lymph nodes, this method offers a faster, safer, and more robust alternative for patients with metastatic solid tumors, which make up 90% of global cancer deaths. This presentation is ideal for: Investors and partners in immuno-oncology and next-gen cell therapy platforms Researchers exploring CAR-T or TIL alternatives for solid tumors Oncology clinicians interested in new tools beyond immune checkpoint blockade Learn more about the Center for Technology Licensing at Cornell: https://ctl.cornell.edu Visit the Ignite website to learn about the gap funding series: https://ctl.cornell.edu/ignite/ Explore the inaugural Ignite Impact Report: https://ctl.cornell.edu/wp-content/up... Watch more Ignite Connect 2026 pitch sessions in this playlist: • Ignite Connect 2026: Accelerating Impact